Expression and purification of recombinant ATF-melittin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris

MANMAN SU1,2, WEIQIN CHANG1, KUN ZHANG1, MANHUA CUI1, SHUYING WU1 and TIANMIN XU1

1Department of Obstetrics and Gynecology, The Second Hospital, Jilin University, Changchun, Jilin 130041; 2Department of Regenerative Medicine, College of Pharmacy, Jilin University, Changchun, Jilin 130021, P.R. China

Received August 4, 2015; Accepted September 22, 2015

DOI: 10.3892/or.2015.4448

Abstract. Melittin is well known to possess cytolytic activity with wide-spectrum lytic properties and its potential use as an agent to treat several types of cancer has been tested. Due to the non-specific toxicity, melittin can impair not only cancer cells but also normal tissue. Thus, tumor-targeted toxins may be helpful for developing novel anticancer therapeutics. The urokinase-type plasminogen activator (uPA) plays a central role in tissue remodelling events occurring in normal physiology and in pathophysiology, including cancer invasion and metastasis. Heartening findings showed that uPA receptor is predominantly expressed on many types of cancer. Therefore, the amino-terminal fragment (ATF) of uPA which was able to identify and bond with cancer cells was used as the cell-targeting domain to make up tumor-targeted toxin in this study. In the present study, pPICZαC-ATF-melittin eukaryotic expression vector was successfully constructed. After transformed into P. pastoris and induced by methanol, rATF-melittin was detected by SDS-PAGE and western blot analysis. After induction with methanol, the expression level of rATF-melittin was 312 mg/l in 80-l fermentor. rATF-melittin was purified to >95% purity using SP Sepharose ion exchange chromatography and source™ 30 RPC with 67.2% recovery. Cell proliferation assay showed that rATF-melittin inhibited growth of SKOV3 cells and had no cytotoxicity effect on normal cells. For the first time, we established a stable and effective rATF-melittin P. pastoris expression system to obtain a high level of expression of secreted rATF-melittin which was purified by a highly efficient purification procedure.

Introduction

Melittin which constitutes 40-60% of dry whole honeybee venom is the most abundant component of whole bee venom (1). This amphipathic peptide of 26 residues contains a hydrophobic stretch of 19 amino acids followed by a cluster of 4 positively charged residues at the C terminus (2). Although it is a small peptide, melittin exhibits a variety of effects such as anti-inflammatory, anti-arthritic and anti-virus effects and pain-relieving effects in various cell types (1,3,4). It also induces cell cycle arrest, growth inhibition and apoptosis in various tumor cells. Its potential use as an agent to treat hepatocellular carcinoma, breast, ovarian and prostate cancer has been tested in vivo or in vitro, with positive outcomes (5-8). Due to the non-specific toxicity, melittin can impair not only cancer cells but also normal tissue. Therefore, many approaches, such as, preparing nanoparticle or recombinant immunotoxin were developed in recent years to make melittin exhibit specific toxicity towards target cells (9-11).

The urokinase-type plasminogen activator (uPA) which is an extracellular serine protease plays a central role in tissue remodelling events occurring in normal physiology and in pathophysiology, including cancer invasion and metastasis. uPA consists of an epidermal growth factor-like domain (EGF-domain; residues 5-46) and a kringle domain (residues 50-131), which together comprise the amino-terminal fragment (ATF), followed by an interdomain linker (residues 132-147), and the catalytic domain (residues 148-411) (12). Its binding to the cell surface receptor (the urokinase-type plasminogen activator receptor, uPAR) via ATF renders it more accessible to plasminogen on the cell surface (13). Active
uPA cleaves inactive plasminogen to generate active plasmin, a broad-specific serine protease, which can degrade a variety of extracellular matrix (ECM) proteins.

uPAR is predominantly expressed on inflammatory cells (14) and many types of cancer, including gastric, colon, breast and ovarian cancers, and cholangiocarcinoma in areas of cancer invasion and metastasis and low levels of uPAR are associated with a better survival (15-18). Moreover, prevention of uPA from binding to uPAR decreases invasion (12). uPA and uPAR are involved in ECM degradation, cancer invasion and metastasis by regulating the plasminogen/plasmin system (19). Thus, uPA-uPAR systems could be an ideal candidate for targeted cancer therapy.

A number of small molecule uPA inhibitors have been developed (20), however, most of these inhibitors lack sufficiently documented specificity (21). Moreover, ATF of uPA was studied as an antagonist inhibitor by competing with uPA for binding to tumor cell surfaces (22). It efficiently inhibited the proliferation, migration and invasiveness of cancer cells in vitro and inhibited tumor invasion in vitro (13).

In the present study, we attempted to prepare a type of fusion protein, which could take advantage of anticancer effects of mellitin and could make use of the specific binding of ATF to upregulated uPAR on tumor surfaces as targeted part of fusion protein at the same time, and apply it to effective targeted treatment. Thereby, recombinant ATF-mellitin (rATF-mellitin) which contains amino acid sequences of ATF and mellitin was expressed in P. pastoris and its anticancer effects were detected in vitro after purification.

Materials and methods

**Strains, vectors and reagents.** T4 DNA ligase, Taq DNA polymerase, plasmid preparation kit, DNA and protein markers, and restrictive enzymes were purchased from Takara Co., Ltd. (Otsu, Japan). The P. pastoris X-33, E. coli XL blue, pPICZαC vector and zeocin antibiotic were obtained from Invitrogen (Carlsbad, CA, USA), and all primers were synthesized by Sangon Biotechnology Co., Ltd. (Shanghai, China). pPICZαC vector without cleavage SteI3 was reconstructed and kept by our laboratory. The murine anti-human urokinase monoclonal antibody was obtained from American Diagnostica Inc. (USA). PCR purification kit was purchased from Sangon Biotechnology Co., Ltd. SP Sepharose XL and SourceTM30 RPC reversed phase hydrophobic chromatography were purchased from Pharmacia (Sweden). HBL100 human breast epithelial cell line and SKOV3 human ovarian cancer cell line were obtained from the type culture collection of the Chinese Academy of Sciences (Shanghai, China).

**Yeast culture media.** P. pastoris was grown in yeast extract peptone dextrose (YPD) (2% peptone, 1% yeast extract and 2% dextrose) or buffered minimal glycerol-complex medium (BMGY) (0.1 M potassium phosphate, 2% peptone, 1% yeast extract, 1.34% YNB and 1% glycerol). Buffered minimal methanol-complex medium (BMMY) was used for protein induction (0.1 M potassium phosphate, 2% peptone, 1% yeast extract, 1.34% YNB and 0.5% methanol). YPD-zeocin plates (1% yeast extract, 2% peptone, 2% dextrose, 2% agar and 0.1 g/l zeocin) were used for selecting positive transformants.

**Construction of recombinant vector pPICZαC-ATF.** The DNA that encodes 155-156 amino acids of uPA was SacII site (ccgcgg) which could be used to connect ATF with the DNA sequence of mellitin. Thus, we attempted to acquire DNA that encodes uPA 1-156 amino acids that includes DNA sequence encoding ATF and interdomain linker. Total RNA was extracted from SKOV3 cells and was used as the template for reverse transcription (RT) reaction. RT reaction was carried out with the following parameters: 42˚C 60 min for RT, and then 94˚C 5 min to inactivate AMV reverse transcriptase. Then the obtained cDNA was used as the template for further PCR to amplify the DNA of human uPA. The upstream primer was: 5'-GGT CCA TCG AAC TGT GAC TG-3' and the downstream primer was: 5'-GGT TCT CGA TGG TGG TGA AT-3'; the temperature of annealing was 50˚C and the polymerase was Takara Ex Taq. The amplified DNA fragment was detected by electrophoresis on 1.0% agarose gel. The amplified human uPA DNA fragment was inserted into cloning vector pMD18ST and the recombinant plasmid which contained correct sequence of uPA was used as template for another PCR. The primers were: 5'-AA TTC TCA TTG TTG TCT CTT TCT AAT C-3' (upstream primer), which contained the XhoI site and the Kex2 site, and 5'-AAT GAA TTC TCT CAA AAT CTT AAA CCC CGG GCC TCA-3' (downstream primer), which contained the EcoRI site. The temperature of annealing was 60˚C and the polymerase was Takara Ex Taq. The amplified DNA fragment was detected by electrophoresis on 1.0% agarose gel. The amplified DNA fragment that contains uPA 1-156 amino acids was digested with XhoI and EcoRI, and were then inserted into the corresponding sites of the expression vector pPICZαC. The recombinant plasmid was transformed into the competent cells of Escherichia coli XL-Blue and the recombinant colonies were selected by zeocin (25 µg/ml) resistance. Both the nucleotide sequences of the inserted DNA and flanking sequence were verified by sequencing with GenomeLab DTCS-Quick Start kit and CEQ 2000 DNA analysis system (Beckman, USA).

**Construction of expression vector pPICZαC-ATF-mellitin.** The DNA that encodes 1-26 amino acids of mellitin was synthesized according to its native amino acid sequences by Sangon Biotechnology Co., Ltd., and was inserted into plasmid pBlueScript II (pBS). For the sake of insertion into pPICZαC-ATF vector, the cohesin end of SacI was added to the 5' end, whereas, termination codon and the cohesin end of EcoRI were added to the 3' end. In order to improve the yield of fusion protein, synonymous codons were replaced by yeast biased codons. The full length DNA sequence which we designed to insert into pPICZαC-ATF was as follows: 5'-GGG TTC ATG AAG AGG ATG GGT TGT ATG GGT ACT GGT TTT CCA GCT GGT ATT ATA GAG AAG AGA CAA CAA TGA G-3'; complementary strand, 5'-AAA TTC TCA TTG TGT CCT CTT CTT CTT TAA GAT CAA AGA AGA AGA AGC TGG CAA ACC AGT CAA AAC CTT CAA AAC AGC AAC ATT CTT CCA TGG G-3'. Annealing was performed as follows: 6 µl 0.5 mmol NaCl and 25 µmol single strand DNA were mixed. Then the compound was boiled for 3 min at 80˚C and cooled down to room temperature gradually. After being annealed, the complementary strands contained cohesive end ofSacI at the
The recombinant plasmid pPICZαC-ATF was digested with SacII and EcoRI, and then the annealed DNA sequence that encodes melittin was inserted into the corresponding sites of pPICZαC-ATF vector. Then the recombinant plasmid was transformed into competent cells of Escherichia coli XL-Blu and the recombinant colonies were selected by zeocin (25 µg/ml) resistance. The positive clones were incubated in LB liquid medium for 12 h, respectively, and the plasmids were extracted by plasmid preparation kit. Both the nucleotide sequences of the inserted DNA and flanking sequence were verified by sequencing with GenomeLab DTCS-Quick Start kit and CEQ 2000 DNA analysis system.

Transformation of P. pastoris and selection of high-level expression colonies. Plasmid DNA pPICZαC-ATF-melittin was linearized with SacI and introduced into competent cells of P. pastoris X-33 strain by electroporation using a MicroPulser (Bio-Rad, USA) according to the pPICZα vector manual. After the electroporation, 1 M ice-cold sorbitol was added immediately, and the cuvette contents were incubated at 30°C for 60 min. The mixture was spread on yeast extract peptone dextrose (YPD) agar plates containing zeocin and cultured at 30°C for 2 days. Antibiotic zeocin was used in the concentration of 0.1 g/l. The blank plasmid of pPICZαC was also transformed as a negative control.

After the transformants with zeocin resistance appeared, some transformants were randomly picked from the plates and initially cultured in a 50-ml conical tube containing 10 ml BMGY medium at 28°C with shaking at 225 rpm for 24 h. The culture media (0.5 ml) was sampled, respectively, centrifuged at 4°C, 10,000 rpm for 5 min, and the cell pellets were used for genomic DNA analysis. The yeast genomic DNA was extracted by plasmid preparation kit. Both the nucleotide sequences of the inserted DNA and flanking sequence were verified by sequencing with GenomeLab DTCS-Quick Start kit and CEQ 2000 DNA analysis system.

Large-scale expression of rATF-melittin. The highest-level expression transformant was cultured in a 5-1 shake flask containing 21 BMGY medium at 28°C until the culture reached OD 600=6.0. The shake flask culture was used to inoculate an 80-l NBS BioFlo 5000 fermentor (New Brunswick Scientific, USA) containing 40 l of fermentation basal salts medium FM 21 supplemented with PTM1 trace salts after glycerol was exhausted. Methanol was added at a rate of 400 ml/h. Sampling of the culture medium was performed at the end of each phase and every 3 h to analyze cells wet weight, optical density, and to measure rATF-melittin expression based on SDS-PAGE analysis (ELISA). The absorbance values at 490 nm were read in ELx800 microplate reader (Bio-Tek, USA) within 2 h.

Purification of rATF-melittin. The supernatant was collected by centrifugation at 15,000 rpm for 10 min and was clarified with a 0.45-µm cellulose membrane. After being diluted four times, the recombinant protein was purified by Ni-NTA chromatography according to the manufacturer’s instructions (Takara, Japan). The protein was eluted with a 500 mM imidazole buffer. The homogeneous protein was concentrated and submitted for further characterization by SDS-PAGE analysis.
times with 20 mM NaAc·HAc (pH 4.0) buffer, the pH of the fermentation broth was adjusted to 4.0 with 1 M acetate acid. A cation exchange chromatographic column (20 ml; SP Sepharose XL, Sweden) was equilibrated with 20 mM NaAc·HAc (pH 4.0) buffer. The supernatant was loaded onto the cation exchange chromatographic column at the rate of 0.5 ml/min. Then the column was extensively washed with the same buffer at the rate of 1 ml/min. The bound protein was eluted with a linear gradient of 0.1-1.0 M NaCl while the flow rate was maintained at the rate of 1 ml/min. Protein elution was monitored by measuring the absorbance at 280 nm and identified by SDS-PAGE analysis. Column effluent containing rATF-melittin was collected and loaded onto a reverse phase column (2.0x15 cm; Source 30; Sweden) which was equilibrated with 0.1% trifluoroacetic acid (TFA) for further purification. rATF-melittin was eluted using 50% methanol that containing 0.1% TFA at the rate of 1 ml/min and monitored by measuring the UV absorbance at 280 nm. Column effluent containing rATF-melittin was concentrated by vacuum distillation and freeze drying to remove methanol. The finally purified rATF-melittin was stored at -80˚C for further studies.

N-terminal amino acid sequence analysis. To determine the N-terminal sequence, the purified rATF-melittin was electrophoresed on 12% SDS-PAGE gel and electroblotted on a PVDF membrane. After being blotted, the PVDF membrane was stained with Coomassie brilliant blue R250, and the rATF-melittin band was cut out and determined by automated Edman degradation performed on a model PPSQ-21A protein sequencer (Shimadzu, Japan).

Cytotoxicity assay of rATF-melittin. The cytotoxicity of rATF-melittin on normal cells was monitored with using Cell Counting Kit-8 (CCK-8) assay. Briefly, human epithelial cells HBL100 were maintained in RPMI-1640 with 10% fetal bovine serum (FBS; HyClone, USA) and 100 U/ml of penicillin/streptomycin, at 37˚C in humidified atmosphere containing 5% CO₂. HBL100 cells were seeded into 96-well plates containing complete medium at a density of 1x10⁴ cells/well and incubated for 24 h followed by different doses of rATF-melittin. HBL100 cells were treated with RPMI-1640 (as control) and 7.5, 15, 30, 60 and 120 µg/ml rATF-melittin for 24 h, respectively. Then the medium was replaced with 200 µl of fresh culture medium and 20 µl CCK-8 solution was added to each well. After being incubated for 2 h, the absorbance was detected at 490 nm using a microplate reader (Bio-Rad Instruments, USA).

Inhibition effects of rATF-melittin on proliferation of ovarian cancer cells. SKOV3 cells were maintained in H-DMEM with 10% FBS and 100 U/ml of penicillin/streptomycin, at 37˚C in humidified atmosphere containing 5% CO₂. To test the inhibition effects of rATF-melittin on proliferation of ovarian cancer cells, SKOV3 cells were seeded into 96-well plates at a density of 1x10⁴ cells/well and were incubated for 24 h followed by different doses of rATF-melittin. SKOV3 cells were treated with H-DMEM (as control) and 7.5, 15, 30, 60 and 120 µg/ml rATF-melittin for 24 h, respectively. CCK-8 assay was performed as above.

Results

Construction and transformation of pPICZαC-ATF-melittin. Results of DNA sequence analysis of the recombinant expression vector pPICZαC-ATF-melittin (data not shown) demonstrated that the DNA sequences encoding human uPA amino acids 1-156 and melittin were correctly inserted into pPICZαC vector and the amino acid sequence of ATF-melittin encoded was identical with that logged in GenBank. After being cultured at 30˚C for 2 days, dozens of transformants with zeocin resistance appeared on YPD agar plates which contained 0.1 g/l zeocin. The PCR analysis of genomic DNA showed that the DNA sequence encoding human uPA amino acids 1-156 and melittin was indeed integrated into pPICZαC vector and the amino acid sequence of ATF-melittin encoded was identical with that logged in GenBank.

Expression and detection of rATF-melittin in P. pastoris. After induction with methanol for rATF-melittin expression, the transformant which presented the highest expression level of rATF-melittin could be used for further experiments. SDS-PAGE analysis of rATF-melittin culture medium indicated rATF-melittin expressed after the inducing of methanol, however, the recombinant protein expression in the transformant containing blank plasmid of pPICZαC was negative.
Based on the amino acids sequence, the calculated molecular weight of rATF-melittin was 20.9 kDa, which was consistent with the result of SDS-PAGE measurement (Fig. 2).

Optimized expression of rATF-melittin in P. pastoris. After a series of experiments, the optimal expression conditions of rATF-melittin were obtained as follows: the optimal pH was 6.5 (Fig. 3A) and the optimal induction time-point was about day 3 for the strain (Fig. 3B) at 28°C and with methanol daily addition concentration of 0.5% (v/v) in 50-ml tube. Under these conditions, the transformant of P. pastoris that presented the highest expression level was chosen for scaled-up protein production.

Large-scale expression and purification of rATF-melittin. The transformant which presented the highest-level expression was cultured to inoculate an 80-l fermentor under the optimal fermentation conditions. Glycerol batch phase lasted ~24 h, and then 50% glycerol was added until the wet weight of culture cells reached 180 g/l. When glycerol was exhausted, OD value abruptly increased. After being induced with methanol, samples were withdrawn every 3 h for SDS-PAGE analysis. The result indicated that during biomass generation phase, the carbon source (glycerol) only met the growth requirement of P. pastoris and there was no recombinant protein expression. Expression of rATF-melittin was initiated when methanol became the unique carbon source. After being induced for 18 h, the transformant presented the highest expression level. The yield was not visibly changed between 18 and 24 h (Fig. 4).

Purification of rATF-melittin and characterization of purified rATF-melittin. The rATF-melittin supernatant was purified with a cation exchange chromatography and a reverse phase chromatography. Using an AKTA Explorer 100 chromatography system, we optimized the purification parameters. The optimal concentration of NaCl for elution was 0.5 M and 50% methanol (containing 0.1% TFA) can elute the bound rATF-melittin from the reverse phase chromatographic column (Fig. 5A). After being purified, 5.19 g rATF-melittin was obtained from 40 l fermentation broth. The concise purification protocol of rATF-melittin is presented in Table I.

The primary purified recombinant protein was identified by western blot analysis. The results demonstrated that the recombinant protein could bind with murine anti-human urokinase monoclonal antibody. No band was observed in lane 3, which was the supernatant before adding methanol (Fig. 5B).
Table I. Purification process of rATF-melittin.

<table>
<thead>
<tr>
<th>Purification steps</th>
<th>Total protein (g)</th>
<th>rATF-melittin (g)</th>
<th>Recovery (%)</th>
<th>Purity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supenatant</td>
<td>12.48</td>
<td>7.74</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>SP Sepharose XL</td>
<td>7.41</td>
<td>6.07</td>
<td>78.4</td>
<td>81.9</td>
</tr>
<tr>
<td>Source™ 30 RPC</td>
<td>5.45</td>
<td>5.19</td>
<td>67.2</td>
<td>95.2</td>
</tr>
</tbody>
</table>

ATF, amino-terminal fragment; rATF, recombinant ATF.

Figure 6. Effects of rATF-melittin on cell proliferation. Dose-effect curve of Inhibition effects of rATF-melittin on growth of ovarian cancer cells SKOV3 (diamonds); dose-effect curve of Inhibition effects of rATF-melittin on growth of human breast epithelial cells HBL100 (squares).

N-terminal sequencing of rATF-melittin yielded the first 14 amino acids as S N E L H Q V P S N C D C L. The N-terminal sequence of rATF-melittin was identical to that of human uPA, confirming the successful expression and purification of rATF-melittin.

Anticancer effects of rATF-melittin. After being treated with rATF-melittin at different doses, some SKOV3 cells showed membrane blebbing, ballooning and chromatin condensation. However, the cells grew well with adherence and the cells were fusiform or diamond shaped in the control group CCK-8 assay was used to detect the quantity of cells. As a result, rATF-melittin treatment caused a dose-dependent inhibition of growth on SKOV3 at 24 h. The inhibition rate is ~80% at the dose of 120 µg/ml. However, the result (Fig. 6) showed that rATF-melittin did not have much influence on the proliferation of normal cells (HBL100). The reason is that uPAR is highly expressed in ovarian cancer cells SKOV3, but it is undetectable in normal cells such as HBL100. In other words, the anticancer effect of rATF-melittin can be exerted when uPA combines with its receptor-uPAR followed by the release of melittin. Thus, the fusion protein expressed showed no obvious toxicity on normal tissues and can be applied to ovarian cancer targeted therapy.

Discussion

Ovarian cancer is the fourth leading cause of cancer mortality among women in Western societies (23). Patients with ovarian cancer have less than 50% chance of 5-year survival and a majority of patients die of disease recurrence or metastasis (24). In case of relapse, therapeutic options are limited, particularly if the relapse occurs within 6 months after completion of primary treatment (25). Consequently, it is clear that new treatments are necessary for ovarian cancer.

Melittin is well known to possess cytolytic activity with wide-spectrum lytic properties. Thus, we chose melittin as the cytotoxic agent to treat cancer cells. However, it is not only cytotoxic to tumors, but also vital to normal cells. It is crucial to control melittin to exhibit specific toxicity towards target cells and to reduce its toxicity towards normal tissue. Melittin had low toxicity when coupled with target peptides (26). Thus, tumor-targeted toxins may be helpful for developing novel anticancer therapeutics.

It has been shown that uPAR is predominantly expressed on many types of cancer, including gastric, colon, breast and ovarian cancers, and cholangiocarcinoma. In the present study, uPA was used as the cell-targeting domain to identify and bind with ovarian cancer cells. uPA was connected with melittin to construct the tumor-targeted toxins-rATF-mellitin. uPA was able to identify cancer cells and led melittin to bond with them, and then perform its lytic properties on the one hand, and on the other rATF-mellitin played a role as antagonist inhibitor by competing with native uPA by binding to tumor cell surfaces.

The present study focuses on expression of the targeted toxin rATF-mellitin, which can be used in ovarian cancer targeted therapy. In the present study, pPICZαC-ATF-mellitin eukaryotic expression vector was successfully constructed. After transformed into \( P. \) \( \text{pastoris} \) and induced by methanol, rATF-mellitin was detected by SDS-PAGE and western blot analysis. After induction with methanol, the expression level of rATF-mellitin was 312 mg/l in 80-l fermentor which contains 40 l fermentation broth. rATF-mellitin was purified to >95% purity using SP Sepharose ion exchange chromatography and source™ 30 RPC with 67.2% recovery. Cell proliferation assay showed that rATF-mellitin inhibited growth of SKOV3 cells and had no cytotoxicity effect on normal cells. For the first time, we established a stable and effective rATF-mellitin \( P. \) \( \text{pastoris} \) expression system to obtain a high level of expression of secreted rATF-mellitin, which was purified by a highly efficient and easy to handle purification procedure.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (81272875, 30973187, 81401221 and 81302242), the Ministry of Education for Young Teacher Foundation of China (20110061120084), the Ministry of Education for Young Scholars Program of Norman Bethune Health Science Center of Jilin University (20142116).

References


